ADX-038

DRUG5 trials

Sponsors

Adarx Pharmaceuticals Inc., ADARx Pharmaceuticals, Inc.

Conditions

Complement 3 Glomerulopathy (C3G)Complement-Mediated Kidney DiseaseGeographic Atrophy Secondary to Age-related Macular DegenerationGeographic atrophy secondary to age-related macular degenerationIC-MPGNImmunoglobulin A Nephropathy (IgAN)Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

RecruitingNCT05876312

ADARx Pharmaceuticals, Inc.Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start: 2023-08-07End: 2028-07-31Target: 50Updated: 2026-06-16

Phase 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

RecruitingNCT06990269

ADARx Pharmaceuticals, Inc.Geographic Atrophy Secondary to Age-related Macular Degeneration

Start: 2025-11-10End: 2030-08-30Target: 240Updated: 2026-09-03

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Not yet recruitingCTIS2025-521752-26-00

Adarx Pharmaceuticals Inc.Complement-Mediated Kidney Disease

Target: 3Updated: 2026-03-02

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Not yet recruitingCTIS2025-521779-30-00

Adarx Pharmaceuticals Inc.Geographic atrophy secondary to age-related macular degeneration

Target: 32Updated: 2026-03-18

Chinese Adults With Kidney Disease

RecruitingNCT07522099

ADARx Pharmaceuticals, Inc.Complement 3 Glomerulopathy (C3G), IC-MPGN, Immunoglobulin A Nephropathy (IgAN)

Start: 2026-05-21End: 2029-01-21Target: 30Updated: 2026-09-03